ReviewBMC endocrine disorders2026
Calcitonin-negative medullary thyroid carcinoma combined with multifocal papillary thyroid carcinoma: a case report and literature review.
Review in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Calcitonin-negative medullary thyroid cancer (CTNMTC) is a rare primary thyroid neuroendocrine carcinoma characterised by medullary thyroid carcinoma (MTC) morphology but without elevated serum calcitonin levels. However, the concurrent occurrence of CTNMTC and papillary thyroid carcinoma (PTC) is even rarer. We report a case of a 68-year-old male patient with normal serum calcitonin levels preoperatively, cytological and histopathological findings consistent with MTC morphology, and no detection of calcitonin by immunohistochemistry but positive reactions for thyroid transcription factor-1 (TTF-1) and synapsin (Syn). Additionally, histopathology indicated multifocal PTC. The diagnosis was calcitonin “double-negative” MTC combined with multifocal PTC, which, to our knowledge, is the first such case reported in the literature. It is prone to misdiagnosis due to its distinctive serologic and immunohistochemical manifestations. We also reviewed the relevant literature to provide a basis for the diagnosis and postoperative follow-up of such patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.